Belong.Life has announced that the American Society of Clinical Oncology has published two abstracts in its 2023 Annual Meeting Abstract Book based on data aggregated from the Belong Beating Cancer Together app.

Personalis, Inc. has announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.

OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.

AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.

Personalis, Inc., National Cancer Center and Ono Pharmaceutical Co., Ltd. have announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.

Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.